CTOs on the Move

Black Diamond Therapeutics

www.blackdiamondtherapeutics.com

 
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Black Diamond Therapeutics raised $20M on 12/12/2018
Black Diamond Therapeutics raised $85M on 01/09/2019

Similar Companies

Biotechlogic

Biotechlogic is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Action Behavior Centers

Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.

Capstone Development Services,

Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...

Inversago Pharma

A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome, diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).